-
公开(公告)号：US11793798B2
公开(公告)日：2023-10-24
申请号：US17521031
申请日：2021-11-08
Applicant: Santen Pharmaceutical Co., Ltd.
Inventor： Naveed Shams , Henk-Andre Kroon , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61P27/06 , A61P27/02 , A61K9/00
CPC classification number: A61K31/444 , A61K9/0048 , A61P27/02 , A61P27/06
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
-
2.发明申请
公开(公告)号：US20150196541A1
公开(公告)日：2015-07-16
申请号：US14592167
申请日：2015-01-08
Applicant: SANTEN PHARMACEUTICAL CO., LTD.
Inventor： Naveed Shams , Henk-Andre Kroon , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61K9/00
CPC classification number: A61K31/444 , A61K9/0048
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
Abstract translation: 提供了用于治疗或预防青光眼或高眼压症的药物制剂，其包含0.0003至0.01％（w / v）异丙基（6 - {[4-（吡唑-1-基）苄基]（吡啶-3-基磺酰基） 氨基甲基}吡啶-2-基氨基）乙酸酯或其盐。
-
公开(公告)号：USRE48183E1
公开(公告)日：2020-09-01
申请号：US16114721
申请日：2018-08-28
Applicant: SANTEN PHARMACEUTICAL CO., LTD.
Inventor： Naveed Shams , Henk-Andre Kroon , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61K9/00 , A61P27/02 , A61P27/06
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
-
4.发明授权
公开(公告)号：US09415038B2
公开(公告)日：2016-08-16
申请号：US14592167
申请日：2015-01-08
Applicant: SANTEN PHARMACEUTICAL CO., LTD.
Inventor： Naveed Shams , Henk-Andre Kroon , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61K9/00
CPC classification number: A61K31/444 , A61K9/0048
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
Abstract translation: 提供了用于治疗或预防青光眼或高眼压症的药物制剂，其包含0.0003至0.01％（w / v）异丙基（6 - {[4-（吡唑-1-基）苄基]（吡啶-3-基磺酰基） 氨基甲基}吡啶-2-基氨基）乙酸酯或其盐。
-
公开(公告)号：US11666563B2
公开(公告)日：2023-06-06
申请号：US16957749
申请日：2018-12-27
Applicant: Santen Pharmaceutical Co., Ltd.
Inventor： Hisashi Kawata , Noriko Kawabata , Naveed Shams
IPC: A61K31/444 , A61K31/5575 , A61K9/00
CPC classification number: A61K31/444 , A61K9/0048 , A61K31/5575
Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
-
公开(公告)号：US20200345713A1
公开(公告)日：2020-11-05
申请号：US16957749
申请日：2018-12-27
Applicant: Santen Pharmaceutical Co., Ltd.
Inventor： Hisashi Kawata , Noriko Kawabata , Naveed Shams
IPC: A61K31/444 , A61K31/5575 , A61K9/00
Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
-
公开(公告)号：US10702511B2
公开(公告)日：2020-07-07
申请号：US16211839
申请日：2018-12-06
Applicant: SANTEN PHARMACEUTICAL CO., LTD.
Inventor： Naveed Shams , Henk-Andre Kroon , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61P27/06 , A61P27/02 , A61K9/00
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
-
公开(公告)号：US20240000763A1
公开(公告)日：2024-01-04
申请号：US18464646
申请日：2023-09-11
Applicant: Santen Pharmaceutical Co., Ltd.
Inventor： Naveed Shams , Henk-Andre Kroon , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61P27/06 , A61P27/02 , A61K9/00
CPC classification number: A61K31/444 , A61P27/06 , A61P27/02 , A61K9/0048
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
-
公开(公告)号：US20190105310A1
公开(公告)日：2019-04-11
申请号：US16211839
申请日：2018-12-06
Applicant: SANTEN PHARMACEUTICAL CO., LTD.
Inventor： Naveed SHAMS , Henk-Andre KROON , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61P27/02 , A61K9/00 , A61P27/06
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
-
公开(公告)号：US09943510B2
公开(公告)日：2018-04-17
申请号：US15212592
申请日：2016-07-18
Applicant: SANTEN PHARMACEUTICAL CO., LTD.
Inventor： Naveed Shams , Henk-Andre Kroon , Hisashi Kawata , Noriko Kawabata
IPC: A61K31/444 , A61K9/00
CPC classification number: A61K31/444 , A61K9/0048
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
